Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 8055-8063

  Orsini, Michael J ^a   Debouck, Christine M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN INHIBITOR; TRANSACTIVATOR PROTEIN;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; NUTRITION; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS INHIBITION;

EID: 0029795044     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.8055-8063.1996     Document Type: Article

References (78)

1. Aguilar-Cordova, E., J. Chinen, L. A. Donehower, J. W. Harper, A. P. Rice, J. S. Butel, and J. W. Belmont. 1995. Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther. 2:161-186.
2. Aiyar, N., E. Baker, H.-L. Wu, P. Nambi, R. M. Edwards, J. J. Trill, C. Ellis, and D. J. Bergsma. 1994. Human AT1 receptor is a single-copy gene: characterization in a stable cell line. Mol. Cell. Biochem. 131:75-86.
3. Aldovini, A., C. Debouck, M. B. Feinberg, M. Rosenberg, S. K. Arya, and F. Wong-Staal. 1986. Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Eschcrichia coli: demonstration of immunogenicity in vivo and expression in vitro. Proc. Natl. Acad. Sci. USA 83:6672-6676.
4. Arya, S. K. 1988. Human and simian immunodeficiency retroviruses: activation and differential transactivation of gene expression. AIDS Res. Hum. Retroviruses 4:175-186.
5. Arya, S. K., B. Beaver, L. Jagodzinski, B. Ensoli, P. J. Kanki, J. Albert, E. M. Fenyo, G. Biberfeld, J. F. Zagury, F. Laure, M. Essex, E. Norrby, F. Wong-Staal, and R. C. Gallo. 1987. New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. Nature (London) 328:548-550.
6. Arya, S. K., C. Guo, S. F. Josephs, and F. Wong-Staal. 1985. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-71
7. Balboni, P. G., R. Bozzini, S. Zucchini, P. C. Marconi, M. P. Grossi, A. Caputo, R. Mansverigi, and G. Barbanti-Brodano. 1993. Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant. J. Med. Virol. 41:289-295.
8. Berkhout, B., A. Gatignol, A. B. Rabson, and K. T. Jeang. 1990. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell 62:757-767.
9. Bozzini, R., C. Rossi, M. P. Grossi, P. C. Marconi, P. G. Balboni, G. Barbanti-Brodano, and A. Caputo. 1995. Effect of tat transdominant negative mutants on HIV-1 replication in Jurkat T cell lines. Minerva Biotechnol. 7:156-161.
10. Brake, D. A., J. Goudsmit, W. Krone, P. Schammel, N. Appelby, R. H. Meloen, and C. Debouck. 1990. Characterization of murine monoclonal antibodies to the Tat protein from human immunodeficiency virus type 1. J. Virol. 64:962-905.
11. Carroll, R., L. Martarano, and D. Derse. 1991. Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/ human immunodeficiency virus type 1 tat gene chimeras. J. Virol. 65:3460-3467.
12. Carroll, R., B. M. Peterlin, and D. Derse. 1992. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J. Virol. 66:2000-2007.
13. Cullen, B. R. 1993. Does HIV-1 tat induce a change in viral initiation rights? Cell 73:417-420.
14. Derse, D., M. Carvalho, R. Carroll, and B. M. Peterlin. 1991. A minimal lentivirus Tat. J. Virol. 65:7012-7015.
15. Echetubu, C. O., H. Rhim, C. H. Herrmann, and A. P. Rice. 1994. Construction and characterization of a potent HIV-2 tat transdominant mutant protein. J. Acquired Immune Defic. Syndr. 7:655-664.
16. Frankel, A. D., D. S. Bredt, and C. O. Pabo. 1988. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 240:70-73.
17. Frankel, A. D., L. Chen, R. J. Cotter, and C. O. Pabo. 1988. Dimerization of the tat protein from human immunodeficiency virus: a cysteine-rich peptide mimics the normal metal-linked dimer interface. Proc. Natl. Acad. Sci. USA 85:6297-6300.
18. Fridell, R. A., L. S. Harding, H. P. Bogerd, and B. R. Cullen. 1995. Identification of a novel human zinc linger protein that specifically interacts with the activation domain of lentiviral Tat proteins. Virology 209:347-357.
19. Garcia, J. A., D. Harrich, L. Pearson, R. Mitsuyasu, and R. B. Gaynor. 1988. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J. 7:3143-3147.
20. Ghosh, S., M. J. Selby, and B. M. Peterlin. 1993. Synergism between tat and VP16 in trans-activation of HIV-1 LTR. J. Mol. Biol. 234:610-619.
21. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
22. Graham, F. L., and A. J. van der eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 54:536-539.
23. Green, M., M. Ishino, and P. M. Loewenstein. 1989. Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58:215-223.
24. Guyader, M., M. Emerman, P. Sonigo, F. Clavel, L. Montagnier, and M. Alizon. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (London) 326:662-669.
25. Hammarskjöld, M.-L. 1991. Manipulation of SV40 vectors, p. 169-180. In E. J. Murray (ed.), Methods in molecular biology. The Humana Press, Inc., Clifton, N.J.
26. Han, P., R. Brown, and J. Barsoum. 1991. Transactivation of heterologous promoters by HIV-1 tat. Nucleic Acids Res. 19:7225-7229.
27. Harrich, D., J. Garcia, R. Mitsuyasu, and R. Gaynor. 1990. TAR-independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J. 9:4417-4423.
28. Hauber, J., M. H. Malim, and B. R. Cullen. 1989. Mutational analysis of the conserved basic domain of human immunodeficiency virus Tat protein. J. Virol. 63:1181-1187.
29. Herskowitz, I. 1987. Functional inactivation of genes by dominant negative mutations. Nature (London) 329:219-222.
30. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
31. Ivanoff, L. Unpublished data.
32. Jeang, K.-T., B. Berkhout, and B. Dropulic. 1993. Effects of integration and replication on transcription of the HIV-1 long terminal repeat. J. Biol. Chem. 268:24940-24949.
33. Jeang, K.-T., R. Chun, N. H. Lin, A. Gatignol, C. G. Glabe, and H. Fan. 1993. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and SpI transcription factor. J. Virol. 67:6224-6233.
34. Jeang, K. T., P. R. Shank, and A. Kumar. 1988. Transcriptional activation of homologous viral long terminal repeats by the human immunodeficiency virus type I or the human T-cell leukemia virus type I tat proteins occurs in the absence of de novo protein synthesis. Proc. Natl. Acad. Sci. USA 85: 8291-8295.
35. Jones, K. A., and B. M. Peterlin. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
36. Kamine, J., and G. Chinnadurai. 1992. Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor SpI. J. Virol. 66:3932-3936.
37. Kamine, J., T. Subramanian, and G. Chinnadurai. 1993. Activation of a heterologous promoter by human immunodeficiency virus type 1 requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators. J. Virol. 67:6828-6834.
38. Kao, S. Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. 1987. Antitermination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature (London) 330:489-493.
39. Kashanchi, F., G. Piras, M. F. Radonovich, J. F. Duvall, A. Fattaey, C.-M. Chiang, R. N. Roeder, and J. N. Brady. 1994. Direct interaction of human TFIID with the HIV transactivator Tat. Nature (London) 367:295-299.
40. Kato, H., H. Sumimoto, P. Pognonec, C.-H. Chen, C. A. Rosen, and R. G. Roeder. 1992. HIV-1 tat acts as a processivity factor in vitro in conjunction with cellular elongation factors. Genes Dev. 6:655-666.
41. Khalili, K. Personal communication.
42. Kuppuswamy, M., T. Subramanian, A. Srinivasan, and G. Chinnadurai. 1989. Multiple functional domains of tat. the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res. 17:3551-3561.
43. Liem, S. E., A. Ramezani, X. Li, and S. Joshi. 1993. The development and testing of retroviral vectors expressing transdominant mutants of HIV proteins to confer anti-HIV-1 resistance. Hum. Gene Ther. 4:625-634.
44. Lisziewicz, J., D. Sun, B. Trapnell, M. Thomson, H.-K. Chang, B. Ensoli, and B. Peng. 1995. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 69:206-212.
45. Liu, J., N. D. Perkins, R. M. Schmid, and G. J. Nabel. 1992. Specific NF-κB suhunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66:3883-3887.
46. Liu, J., C. Woffendin, Z. Yang, and G. J. Nabel. 1994. Regulated expression of a dominant negative form of Rev improves resistance to H1V replication in T cells. Gene Ther. 1:32-37.
47. Lu, X., T. M. Welsh, and B. M. Peterlin. 1993. The human immunodeficiency type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by tat. J. Virol. 67:1752-1760.
48. Lu, Y., P. M. Loewenstein, Z. Zhang, and M. Green. 1995. In vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAP. J. Virol. 69:3017-3023.
49. Luo, Y., S. J. Madore, T. G. Parslow, B. R. Cullen, and B. M. Peterlin. 1993. Functional analysis of interactions between tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. J. Virol. 67:5617-5622.
50. Luo, Y., and B. M. Peterlin. 1993. Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 tat is required for optimal interactions between tat and TAR. J. Virol. 67:3441-3445.
51. Madore, S. J., and B. R. Cullen. 1993. Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 tat function. J. Virol. 67:3703-3711.
52. Madore, S. J., and B. R. Cullen. 1995. Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators. Virology 206: 1150-1154.
53. Marciniak, R. A., and P. A. Sharp. 1990. HIV-1 tat protein promotes formation of more-processive elongation complexes. EMBO J. 10:4189-4196.
54. Modesti, N., J. Garcia, C. Debouck, M. Peterlin, and R. Gaynor. 1991. Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol. 3:759-768.
55. Myers, G., S. F. Josephs, J. A. Berzofsky, A. B. Rabson, T. F. Smith, and F. Wong-Staal. 1990. Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N. Mex.
56. Orsini, M. Unpublished data.
57. Pearson, L., J. Garcia, F. Wu, N. Modesti, J. Nelson, and R. Gaynor. 1990. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc. Natl. Acad. Sci. USA. 87:5079-5083.
58. Ptashne, M. 1988. How eukaryotic transcriptional activators work. Nature (London) 335:683-689.
59. Rappaport, J., S. J. Lee, K. Khalili, and S. F. Wong. 1989. The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain. New Biol. 1:101-110.
60. Reddy, M. V., M. Desai, J. Jeyapaul, D. D. Prasad, T. Seshamma, D. Palmeri, and S. A. Khan. 1992. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1. Oncogene 7:1743-1748.
61. Rice, A. P., and F. Carlotti. 1990. Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type I Tat protein. J. Virol. 64:1864-1868.
62. Rice, A. P., and F. Chan. 1991. Tat protein of human immunodeficiency virus type 1 is a monomer when expressed in mammalian cells. Virology 185:451-454.
63. Selby, M. J., and B. M. Peterlin. 1990. Trans-activation by HIV-1 tat via a heterologous RNA binding protein. Cell 62:769-776.
64. Siomi, H., H. Shida, M. Maki, and M. Hatanaka. 1990. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 64:1803-1807.
65. Southgate, C., M. L. Zapp, and M. R. Green. 1990. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature (London) 345:640-642.
66. Southgate, C. D., and M. R. Green. 1991. The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev. 5:2496-2507.
67. Subramanian, T., R. Govindarajan, and G. Chinnadurai. 1991. Heterologous basic domain substitutions in the HIV-1 Tat protein reveal an argininerich motif required for transactivation. EMBO J. 10:2311-2318.
68. Subramanian, T., M. Kuppuswamy, L. Venkatesh, A. Srinivasan, and G. Cinnadurai. 1990. Functional substitution of the basic domain of the HIV-1 trans-activator, tat, with the basic domain of the functionally heterologous rev. Virology 176:178-183.
69. Sullenger, B. A., H. F. Gallardo, G. E. lingers, and E. Gilboa. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65:6811-6816.
70. Suñé, C., and M. A. García-Blanco. 1995. Transcriptional trans activation by human immunodeficiency type 1 Tat requires specific coactivators that are not basal factors. J. Virol. 69:3098-3107.
71. Taylor, J. P., R. Pomerantz, O. Bagasra, M. Chowdhury, J. Rappaport, K. Khalili, and S. Amini. 1992. TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation. EMBO J. 11:3395-3403.
72. Taylor, J. P., R. J. Pomerantz, G. V. Raj, F. Kashanchl, J. N. Brady, S. Amini, and K. Khalili. 1994. Central nervous system-derived cells express a κB-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat. J. Virol. 68:3971-3981.
73. Tiley, L. S., P. H. Brown, and B. R. Cullen. 1990. Does the human immunodeficiency virus tat trans-activator contain a discrete activation domain? Virology 178:560-567.
74. Tiley, L. S., S. J. Madore, M. H. Malim, and B. R. Cullen. 1992. The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev. 6:2077-2087.
75. Triezenberg, S. J., R. C. Kingsbury, and S. L. McKnight. 1988. Functional dissection of VP16, the transactivator of herpes simplex virus immediate early gene expression. Genes Dev. 2:718-729.
76. Valerie, K., A. Delers, C. Bruck, C. Thiriart, H. Rosenberg, C. Debouck, and M. Rosenberg. 1988. Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature (London) 333:78-81.
77. Webster, L. C., and R. P. Ricciardi. 1991. trans-dominant mutants of E1A provide genetic evidence that the zinc finger of the trans-activating domain hinds a transcription factor. Mol. Cell. Biol. 11:4287-4296.
78. Weeks, K. M., and D. M. Crothers. 1993. RNA targeting by the HIV-1 Tat protein. Perspect. Drug Discov. Des. I:225-234.